Royalty Pharma Plc stock is traded at $70.01, with a volume of 3,532,642. It is up +0.81% in the last 24 hours and up +22.98% over the past month. Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Previous Close:
$69.45
Open:
$69.04
24h Volume:
3,532,642
Relative Volume:
0.94
Market Cap:
$31.17B
Revenue:
$2.44B
Net Income/Loss:
$1.36B
P/E Ratio:
36.67
EPS:
$1.91
Net Cash Flow:
$574.14M
1W Performance:
+3.63%
1M Performance:
+22.98%
6M Performance:
+35.55%
1Y Performance:
+79.70%
1-Day Range:
$68.88$70.27
1-Week Range:
$66.52$70.27
52-Week Range:
$37.31$70.27
Royalty Pharma Plc Stock (RPRX) Company Profile
Name
Royalty Pharma PlcSector
HealthcareIndustry
BiotechnologyPhone
(212) 883-0200Address
110 EAST 59TH STREET, NEW YORK, NY, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS